Alligator Bioscience
Clinical-stage biotech developing tumor-directed immuno-oncology antibody drugs.
ATORX | ST
Overview
Corporate Details
- ISIN(s):
- SE0000767188 (+8 more)
- LEI:
- 549300E15VI0MB7LXV19
- Country:
- Sweden
- Address:
- C/O Medicon Village, 223 81 Lund
- Sector:
- Manufacturing
Description
Alligator Bioscience is a clinical-stage biotechnology company that develops tumor-directed immuno-oncology antibody drugs. The company's core strategy is to activate the patient's own immune system to fight cancer. It utilizes a proprietary technology platform for the discovery and development of novel antibody-based pharmaceuticals. The development pipeline features several drug candidates, including its lead asset mitazalimab, a CD40 agonist. The company specializes in creating therapeutics that are designed to be effective against various forms of cancer.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2019-03-07 11:45 |
Alligator Bioscience: First Patient Dosed in Phase I study of ATOR-1015
|
English | 79.0 KB | ||
| 2019-02-14 08:00 | Swedish | 2.1 MB | |||
| 2019-02-14 08:00 | English | 2.1 MB | |||
| 2019-01-29 08:00 |
Alligator Bioscience publishes clinical phase I data for ADC-1013 in the Intern…
|
English | 76.5 KB | ||
| 2019-01-29 08:00 |
Alligator Bioscience publicerar klinisk fas I-data för ADC-1013 i International…
|
Swedish | 108.7 KB | ||
| 2019-01-07 13:00 |
Alligator Bioscience launches RUBY™, a novel concept in bispecific antibody for…
|
English | 77.0 KB | ||
| 2019-01-07 13:00 |
Alligator Bioscience lanserar RUBY™, ett nytt formatkoncept för bispecifika ant…
|
Swedish | 111.1 KB | ||
| 2018-12-11 08:00 |
Alligator Bioscience starts clinical phase I study with ATOR-1015
|
English | 107.4 KB | ||
| 2018-12-11 08:00 |
Alligator Bioscience startar klinisk fas I-studie med ATOR-1015
|
Swedish | 109.9 KB | ||
| 2018-11-09 06:00 |
Alligator Bioscience and Aptevo Therapeutics Present New Preclinical Data for A…
|
English | 130.2 KB | ||
| 2018-11-09 06:00 |
Alligator Bioscience och Aptevo Therapeutics presenterar nya prekliniska data f…
|
Swedish | 123.0 KB | ||
| 2018-11-07 17:00 |
Alligator Bioscience erhåller mångmiljonintäkt - AbClon-partner utnyttjar opt…
|
Swedish | 106.2 KB | ||
| 2018-11-07 17:00 |
Alligator Bioscience to receive million-dollar payments - AbClon partner exerci…
|
English | 89.7 KB | ||
| 2018-11-06 11:15 |
Valberedning utsedd inför årsstämma 2019 i Alligator Bioscience AB
|
Swedish | 82.3 KB | ||
| 2018-11-06 11:15 |
Nomination Committee appointed in respect of AGM 2019 in Alligator Bioscience AB
|
English | 83.9 KB |
Automate Your Workflow. Get a real-time feed of all Alligator Bioscience filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Alligator Bioscience
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Alligator Bioscience via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-02-28 | Peter Ostler | Other | Sell | 1,658,134 | 179,045.31 SEK |
| 2024-04-11 | Staffan Encrantz | Other | Sell | 44,108,581 | 47,196,181.67 SEK |
| 2022-10-27 | Sören Bregenholt Frederiksen | Other | Buy | 52,000 | 72,748.00 SEK |
| 2022-10-25 | Marie Svensson | Other | Buy | 12,000 | 16,632.00 SEK |
| 2022-08-19 | Sören Bregenholt Frederiksen | Other | Buy | 13,906 | 25,726.10 SEK |
| 2022-08-18 | Sören Bregenholt Frederiksen | Other | Buy | 31,094 | 56,911.35 SEK |
| 2022-05-31 | Peter Ostler | Other | Buy | 100,000 | 151,500.00 SEK |
| 2022-05-04 | Sören Bregenholt Frederiksen | Other | Buy | 30,000 | 50,895.00 SEK |
| 2022-05-02 | Sören Bregenholt Frederiksen | Other | Buy | 30,000 | 50,811.00 SEK |
| 2022-04-30 | Sören Bregenholt Frederiksen | Other | Buy | 30,000 | 51,171.00 SEK |
Peer Companies
